Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 12/01 11:31:00 am
74.24 CHF   +1.09%
02:45aNew Keywords Studios CEO Takes Office
MT
01:16aZero-sugar Oreos see weak China response despite healthy snacking trend
RE
11/30Novartis To Explore All Options For Generics Business Unit Sandoz
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis in New Agreement With BioNTech to Help Manufacture Covid-19 Vaccine

10/20/2021 | 11:43pm EST

By Cecilia Butini

Novartis AG said Thursday that it has signed a new agreement with BioNTech SE to support the production of the company's and Pfizer Inc.'s Covid-19 vaccine at one of its facilities.

The Swiss pharma major said it will support the fill-and-finish operations of the vaccine, meaning the transfer of the vaccine substance into vials under sterile conditions.

It will do so at its facility in Ljubljana, Slovenia, and will begin operations in the first half of 2022, Novartis said. At least 24 million vaccine doses will be filled there, the company said.

The agreement follows another one which was signed earlier this year and which had Novartis filling and finishing more than 50 million doses at its site in Stein, Switzerland.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

10-21-21 0143ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -4.91% 334.48 Delayed Quote.331.48%
NOVARTIS AG 1.09% 74.24 Delayed Quote.-12.21%
PFIZER, INC. 1.75% 54.67 Delayed Quote.45.97%
All news about NOVARTIS AG
02:45aNew Keywords Studios CEO Takes Office
MT
01:16aZero-sugar Oreos see weak China response despite healthy snacking trend
RE
11/30Novartis To Explore All Options For Generics Business Unit Sandoz
MT
11/30Novartis chairman says all options open for Sandoz unit - report
RE
11/29NOVARTIS : at ASH
PU
11/26Roche Shareholders Approve Deal to Buy Back Novartis' Stake in Swiss Drugmaker
MT
11/26Roche shareholders approve deal to buy Novartis's $20.7 billion stake
RE
11/26Roche Shareholders OK $21 Billion Repurchase Deal With Novartis
MT
11/26Roche shareholders approve deal to buy Novartis's $20.7 billion stake
RE
11/26NOVARTIS AG : Gets a Neutral rating from UBS
MD
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 52 044 M - -
Net income 2021 13 509 M - -
Net Debt 2021 22 425 M - -
P/E ratio 2021 13,0x
Yield 2021 4,11%
Capitalization 181 B 181 B -
EV / Sales 2021 3,90x
EV / Sales 2022 3,67x
Nbr of Employees 108 000
Free-Float 85,7%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 79,85 $
Average target price 98,88 $
Spread / Average Target 23,8%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-12.21%178 183
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871